Skip to main content

Table 2 Positivity rate of Ancylostoma in two sets of dogs on St. Kitts

From: Ancylostoma in dogs in the Caribbean: a review and study from St. Kitts, West Indies

 

Field Studya 2014

Clinic Dataa 2018–2019

P-valued

 

N (%)

Positive (%)

P-valuec

N (%)

Positive (%)

P-valuec

Age (months)

 < 6

4 (4.1)

1 (25.0)

0.3899

52 (22.4)

5 (9.6)

0.2924

0.0002

 6–12

17 (17.5)

10 (58.8)

27 (11.6)

5 (18.5)

 > 12

76 (78.4)

48 (63.2)

153 (65.9)

13 (8.5)

Sex

 Male

45 (46.4)

30 (66.7)

0.3741

108 (46.8)

12 (11.1)

0.7401

1.0

 Female

52 (53.6)

29 (55.8)

123 (53.2)

11 (8.9)

Anthelmintic useb

 Monthly

5 (5.2)

1 (20.0)

0.0299

121 (52.2)

6 (5.0)

0.0154

0.0001

 Other

35 (36.1)

18 (51.4)

36 (15.5)

4 (11.1)

 None

57 (58.8)

40 (70.2)

75 (32.3)

13 (17.3)

Total

97

59 (60.8)

 

232

23 (9.9)

 

0.0001

  1. aThe 2014 data represent dogs with limited veterinary care. Clinic data, January 2018–December 2019, represent dogs with greater veterinary care
  2. bMonthly defined as a Dirofilaria immitis preventative excluding Revolution® (selamectin). Other defined as an anthelmintic administered within the previous 6 months with activity against Ancylostoma. None indicates the owner had not administered any anthelmintic in the previous 6 months (2014 data) or there were no records of dispensing an anthelmintic (2018–2019 data)
  3. cBased on a chi-square or Fisher’s exact test
  4. dBased on a χ2 or Fisher’s exact test; comparison between the two study groups